Mushrooms are Groovy Baby


August 9, 2021·4 min readIn this article:

Explore the topics mentioned in this article

NEW YORK, Aug. 9, 2021 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced its mid-year 2021 business and clinical update.

(PRNewsfoto/Seelos Therapeutics, Inc.)
(PRNewsfoto/Seelos Therapeutics, Inc.)

“In the first half of 2021, the Seelos team continued to execute at a very high level. Part 1 of the SLS-002 study demonstrated rapid antidepressant and anti-suicidal effects with a well-tolerated safety profile. We have begun the placebo-controlled Part 2 of this registration directed study and plan to enroll in up to 30 sites,” said Raj Mehra Ph.D., Chairman and CEO of Seelos. “The SLS-005 IV trehalose program’s pivotal study in ALS, which was accepted into the HEALEY ALS Platform Trial at Harvard, plans to commence dosing patients in the third quarter as well. We have begun additional in vivo studies with our gene therapy program SLS-004 after demonstrating its capability of reducing alpha-synuclein expression targeting Parkinson’s disease, and we continue to evaluate additional indications for both SLS-002 and SLS-005.”

They maintain their neutral rating. Price targets are all over the place ranging from $2.50-$15.00 with an average price target of $8.30.




MNMD this one was OTC before

this is all you, what the one the penny bros like?

Yes, this was the big psychedelic play last year when it was on the OTCs. The current Woodstock Summer of Love stocks that there’s hype over are Cybin (CYBN), Compass (CMPS), Entheon Bio (ENTBF), Better Life (BETRF) and one other one… cant get into my IRB account to see my list.

ATAI Peta Theil Baby

but check this you also get a piece of Compass Pathways:

And another one called Cybin!… maybe

Compass leads the for-profit public psych companies in terms of how far along their trials are. This gives ATAI a great chance to capitalize off of their ~20% stake in Compass without having to fund the ongoing trials. As of their most recent filing (today), ATAI has 10 drug development programs and 6 technology programs under their umbrella, all with varying ownership percentages.

Should I Grandpa ETF it bro? hpsyf

I love Canadia!

Leave a Reply

Your email address will not be published. Required fields are marked *